Konyne 80 is approved by the Food and Drug Administration (FDA) to control and prevent bleeding in adults with hemophilia B. Konyne 80 may also be used to reverse coumarin anticoagulant-induced hemorrhage and treat bleeding in people with hemophilia A who have inhibitors to clotting factor VIII. The technical name of Konyne 80 is Factor IX complex (human).
Konyne 80 is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.
How do I take it?
Prescribing information states that Konyne 80 is given as an intravenous injection.
Konyne 80 comes as a powder that must be reconstituted before injection.
The FDA-approved label for Konyne 80 lists common side effects including fever, flushed skin, tingling sensation, headache, and chills.
Rare but serious side effects listed for Konyne 80 include thromboembolic events and the transmission of infections.
For more details about this treatment, visit:
Konyne 80 – Kiessig
Treatment of Hemophilia – Hemophilia Federation of America